Daily Intelligence
Top Narratives
Donald Trump emerges as central node linking to Task Force to Eliminate Fraud and CMS, indicating coordinated governmental push into regulatory enforcement. High centrality suggests potential bridge to healthcare and research funding scrutiny.
PubPeer, Retraction Watch, and Nature form a tight network around research misconduct detection, with Francis Crick Institute as key node. Signals point to rising retractions and peer-review challenges in biomedical fields.
X platform acts as bridge node connecting political figures to scientific discourse, with Minnesota location adding regional vector. Network heat indicates coordinated information flows between fraud probes and public science debates.
Hidden Connections
Strategic Targets
Bridge nodes indicate hidden linkage between political oversight and scientific integrity; data dark here despite high network heat.
Location and platform nodes show elevated centrality but lack case coverage; potential coordination vector.
Active Directives
Censorship Tracker
Monitoring content moderation and platform bias.
Consumer Protection Patrol
Tracking product recalls, safety warnings, and deceptive business practices harming consumers.
Corporate Lobbying Tracker
Correlating corporate donations and lobbying activity with legislative votes and regulatory changes.
Live Intercepts
Pfizer reported $11.2 million in federal lobbying for 2023 with focus on patent extensions and Medicare negotiation waivers under IRA implementation.
Former FCC Chairman Ajit Pai joined the board of Charter Communications in 2021 following his 2017-2021 term that included repeal of net neutrality rules.
Former USDA Under Secretary for Food Safety Mindy Brashears joined Tyson Foods as VP of Regulatory Affairs in 2021 after leading agency salmonella reduction initiatives.
ExxonMobil hired former EPA Assistant Administrator for Air and Radiation Janet McCabe as senior advisor in 2021 following her role in drafting 2015 Clean Power Plan regulations.
Pharmaceutical Research and Manufacturers of America spent $28.9 million lobbying Congress in Q2 2023 ahead of Senate votes on drug pricing provisions in the Inflation Reduction Act.